| No. |
DrugBank |
Drug (Description in trials)
[Number of descriptions] |
KEGG DRUG * | KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 | Acetate | [76] 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
| 2 | Acetazolamide | [2] Acetazolamide; Acetazolamide sandoz 250; | D00218
D01196 |
[13] CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
[7] Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
[6] 13, 90, 115, 155, 225, 230 |
| 3 | Aflibercept | [1] Aflibercept; | D09574 |
[3] PGF, VEGFA, VEGFB |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[2] 90, 166 |
| 4 | Amino acids | [2] Amino acids; Free amino acids intake; | - |
- |
- |
[4] 70, 90, 240, 298 |
| 5 | Betamethasone | [6] Betamethasone; Betamethasone acibutate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.; | D00244
D00972
D01357
D01402
D01637
D02032
D02286 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[6] 2, 46, 65, 90, 96, 235 |
| 6 | Brimonidine | [6] 100 µg brimonidine tartrate implant; 200 µg brimonidine tartrate implant; 400 µg brimonidine tartrate implant; Brimonidine; Brimonidine tartrate; Brimonidine tartrate posterior segment drug delivery system (brimo ps dds) applicator system; | D02076
D07540 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[1] 90 |
| 7 | Carbidopa | [60] Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental); | D00558 |
[1] DDC |
[9] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
[8] 2, 4, 6, 13, 17, 90, 164, 201 |
| 8 | Cenegermin | - | D11028 |
[1] NGFR |
[8] Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer |
[1] 90 |
| 9 | Cholesterol | [9] 3h-cholesterol bound to albumin; Cholesterol; Cholesterol supplementation; Crystalline cholesterol oil-based suspension; Egg substitute, without cholesterol; Egg yolk preparation with cholesterol; Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); | D00040 |
- |
- |
[7] 19, 90, 160, 259, 261, 301, 310 |
| 10 | Ciclosporin | [4] Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a; | D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[44] 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 11 | Ciliary neurotrophic factor | [2] Ciliary neurotrophic factor; Ciliary neurotrophic factor implant nt-501; | - |
- |
- |
[1] 90 |
| 12 | Dexamethasone | [35] Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone; | D00292
D00975
D01510
D01615
D01632
D01948
D02174
D02591
D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[20] 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
| 13 | Doconexent | - | - |
- |
- |
[7] 6, 49, 90, 94, 240, 299, 301 |
| 14 | Dorzolamide | [1] Dorzolamide; | D00653
D07871 |
[13] CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
[7] Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
[1] 90 |
| 15 | Fluocinolone | [2] Fluocinolone; Fluocinolone acetonide; | - |
- |
- |
[1] 90 |
| 16 | Fluocinolone acetonide | [1] Fluocinolone acetonide; | D01825 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 90 |
| 17 | Ginkgo biloba | [2] Ginkgo biloba; Ginkgo biloba pills sig: 300mg/tid; | - |
- |
- |
[3] 6, 13, 90 |
| 18 | Hydroxychloroquine | [16] Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | D08050 |
- |
- |
[18] 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
| 19 | Interferon gamma-1b | [2] Interferon gamma-1b; Interferon gamma-1b (actimmune); | D00747 |
[2] IFNGR1, IFNGR2 |
[19] Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
[7] 65, 85, 90, 228, 299, 301, 326 |
| 20 | L-Cysteine | - | D00026
D02326 |
- |
- |
[9] 6, 13, 19, 84, 85, 88, 90, 254, 296 |
| 21 | Levodopa | [87] Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa and levodopa 25mg/100mg; Carbidopa levodopa; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: levodopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Intravenous levodopa; Iv levodopa; Levodopa; Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa (l-dopa); Levodopa (l-dopa) + standard care; Levodopa / benserazid; Levodopa / benserazide 200 + 50 mg; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg a cap; Levodopa 125 mg a cap; Levodopa 150 mg a cap; Levodopa 25mg/100mg; Levodopa 75 mg a cap; Levodopa acute challenge; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa and decarboxylase inhibitor; Levodopa and domperidone; Levodopa benserazide madopar; Levodopa benserazide teva italia; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa cr (controlled release); Levodopa cyclops; Levodopa dc.it fu; Levodopa dispersible; Levodopa infusion; Levodopa mr; Levodopa powder for inhalation; Levodopa test; Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa, decarboxylase inhibitor and comt inhibitor; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/benzeraside; Levodopa/benzerazide; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Levodopa/ddci; Nacom levodopa+cardidopa; Nd0612 (levodopa/carbidopa solution); Oral levodopa and carbidopa; Oral levodopa/carbidopa; Rasagiline mesylate with levodopa; Safinamide + levodopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Tvp-1012 (1 mg/day) with levodopa; Tvp-1012 1mg with levodopa; | D00059 |
[5] DRD1, DRD2, DRD3, DRD4, DRD5 |
[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
[7] 2, 4, 6, 17, 90, 164, 201 |
| 22 | Lutein | [3] Lutein; Lutein (10 or 30 mg/day) capsules; Lutein plus zeaxanthin; | - |
- |
- |
[2] 90, 164 |
| 23 | Medical Cannabis | - | - |
- |
- |
[6] 2, 6, 13, 90, 96, 97 |
| 24 | Melatonin | [10] 3 mg melatonin; 5 mg melatonin; Circadin ( inn= melatonin); Diazepam, melatonin; Dtr melatonin (nih cc pds); Hourly dosing of the nychtemeral secretion of melatonin; Melatonin; Melatonin cr; Melatonin pr; Melatonin(circadin®); | D08170 |
[2] MTNR1A, MTNR1B |
[2] Circadian entrainment, Neuroactive ligand-receptor interaction |
[8] 6, 13, 46, 49, 90, 97, 144, 202 |
| 25 | Minocycline | [7] Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850
D05045 |
- |
- |
[14] 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
| 26 | Nerve Growth Factor | [2] Nerve growth factor; Recombinant human nerve growth factor (rhngf); | - |
- |
- |
[2] 3, 90 |
| 27 | Nilvadipine | [1] Nilvadipine; | D01908 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 90 |
| 28 | Oxygen | [9] Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture; | D00003 |
- |
- |
[18] 5, 6, 17, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 211, 226, 299, 330 |
| 29 | Phosphate ion | - | - |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
| 30 | Tocopherol | [5] Alpha-tocopherol; Gamma-tocopherol; Tocopherol; Tocopherol (vit e); Tocopherol acetate; | D02332 |
- |
- |
[4] 13, 49, 90, 257 |
| 31 | Triamcinolone | [10] Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection; Triamcinolone; Triamcinolone acetonide; Triamcinolone acetonide and normal saline solution; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); | D00385
D00983
D00984
D00985
D06216 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[18] 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 |
| 32 | Unoprostone | [3] Uf-021 (isopropyl unoprostone); Uf-021(isopropyl unoprostone); Unoprostone; | D08661 |
[1] PTGFR |
[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway |
[1] 90 |
| 33 | Valproic Acid | [3] Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine; | D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 34 | Vitamin A | [1] Vitamin a; | D00069
D06543 |
[2] RARA, RARB |
[8] Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
[4] 13, 49, 53, 90 |
| 35 | Vitamin E | [8] Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium; | D02331 |
- |
- |
[12] 2, 6, 13, 20, 46, 49, 90, 96, 97, 206, 299, 317 |
| 36 | Zuretinol acetate | [1] Zuretinol acetate; | - |
- |
- |
[1] 90 |